Catalyst
Slingshot members are tracking this event:
Fitusiran (ALN-AT3) for the treatment of hemophilia and rare bleeding disorders (RBD) Present additional data from the ongoing Phase 1 trial in mid-2016.
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ALNY | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 25, 2016
Occurred Source:
http://www.alnylam.com/capella/presentations/interim-data-from-fitusiran-ph-1-trial/
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Fitusiran, Aln-at3, Rare Bleeding Disorders, Phase 1 Data, Hemophilia
